Wanbury Gets Brazil Approval for Sertraline, Lands ₹15 Crore Metformin Deal

OTHER
Whalesbook Logo
AuthorKavya Nair|Published at:
Wanbury Gets Brazil Approval for Sertraline, Lands ₹15 Crore Metformin Deal
Overview

Wanbury Limited has won ANVISA approval for Sertraline Form II in Brazil, reinforcing its leading 75% market share there. The company also secured customer approval for a special metformin DC grade, creating a potential ₹15 crore annual business opportunity. These wins boost Wanbury's market position and diversify revenue.

Wanbury Expands Market Reach with Brazil Sertraline Approval and ₹15 Crore Metformin Deal

Wanbury already holds about 75% of the Sertraline market in Brazil. This new Form II approval is expected to further solidify that strong position. Separately, a major customer's approval for a special Metformin DC grade unlocks a potential ₹15 crore annual business opportunity.

Key Developments

Wanbury Limited has announced significant regulatory achievements that will strengthen its market position and expand its revenue base.

The company received Sertraline Form II approval from ANVISA, Brazil's health regulatory agency. This approval is expected to further consolidate its already dominant 75% market share for Sertraline in Brazil.

In a separate move, Wanbury secured approval from a major customer for a special grade of Metformin DC. This specialized product represents an estimated potential annual business opportunity of approximately ₹15 crore.

Why This Matters

ANVISA approval is crucial for pharmaceutical companies aiming for strong access and presence in the large Brazilian market. For Wanbury, with its substantial Sertraline market share, this approval reinforces its commitment to quality and regulatory compliance, further solidifying its foothold.

The Metformin DC grade approval signifies a strategic step beyond bulk API supply. It opens a new, significant revenue stream with a specific major client, demonstrating the company's ability to meet specialized product needs.

Company Background

Wanbury Limited, established in 1988, is an India-based pharmaceutical company with a strong focus on Active Pharmaceutical Ingredients (APIs) and branded formulations, exporting to over 70 countries.

Wanbury is a significant player in the global API market, recognized for its substantial capacity in key molecules like Metformin HCl (holding approximately 11% of global capacity) and Sertraline HCl (approximately 30% of global capacity).

However, the company has faced past regulatory scrutiny. In 2016, it was investigated by the Maharashtra FDA for alleged illegal export of Metformin hydrochloride, involving outsourcing and re-labelling issues. In 2017, SEBI also issued an order against a promoter entity for disclosure non-compliance related to pledged shares.

Impact of the Approvals

  • Market Share Consolidation: The Sertraline Form II approval will likely solidify Wanbury's leading position in the Brazilian antidepressant market.
  • New Revenue Stream: The ₹15 crore annual potential from the Metformin DC grade diversifies revenue sources and adds a specific, customer-focused product.
  • Enhanced Regulatory Credibility: ANVISA approval from a stringent regulatory body bolsters Wanbury's credentials in key export markets.
  • Product Diversification: While Metformin and Sertraline remain core products, this move signals a strategy to offer specialized grades and meet specific customer needs.

Risks to Watch

  • Product Concentration: Metformin HCl and Sertraline HCl together accounted for approximately 85–90% of Wanbury's API revenues in FY24-FY25, posing a concentration risk.
  • Regulatory Environment: While ANVISA approval is positive, the pharmaceutical industry is subject to evolving regulatory landscapes in export markets.
  • Past Regulatory Scrutiny: Though not directly related to the current approvals, past incidents concerning export practices necessitate continued diligence and compliance.

Industry Context

Wanbury operates within India's robust API manufacturing sector, which includes giants like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Aurobindo Pharma, and Cipla. While these peers often have broader portfolios and larger scale, Wanbury has carved out strong positions in specific high-volume APIs like Metformin and Sertraline. Many leading Indian API players, similar to Wanbury, maintain multiple USFDA and EU GMP-certified facilities and derive a significant portion of their revenue from regulated markets.

Key Financial Metrics

  • Wanbury's revenue was approximately $74.8 million on a trailing twelve-month (TTM) basis as of December 2025.
  • For FY25, EBITDA margins stood at approximately 12.5%, an improvement from historical ~5-6% margins.
  • Exports constituted around 70% of total revenues in FY25, with APIs making up about 88% of the revenue mix.

What to Track Next

  • Realization of Metformin Deal: Monitor the ramp-up of business from the newly approved Metformin DC grade customer.
  • Brazil Market Performance: Observe the tangible impact of the Sertraline Form II approval on market share and sales in Brazil.
  • New Product Pipeline: Track the progress of upcoming API launches planned for FY26 and FY27, aimed at reducing product concentration.
  • Financial Performance: Watch for continued improvement in profitability and revenue growth, particularly from export markets.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.